Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581 Bertagnolli, M. M. , Niedzwiecki, D. , Hall, M. , Jewell, S. D. ... - ASCO - J. Clin. Oncol. - 2009 Abstract - Secondary - Primary - GI - C9581
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803 Bertagnolli, Monica M. , Niedzwiecki, Donna , Compton, Carolyn C. ... - - J Clin Oncol - 2009 Manuscript - Secondary - Primary - GI - CALGB-150705 , CALGB-89803
p27Kip1 in Stage III Colon Cancer: Implications for Outcome Following Adjuvant Chemotherapy in CALGB 89803 Bertagnolli, Monica M. , Warren, Robert S. , Niedzwiecki, Donna ... - - Clin Cancer Res - 2009 Manuscript - Secondary - Primary - GI - CALGB-150705 , C89803
Determination of Utility Scores for Control of Chemotherapy-Induced Nausea or Vomiting—CALGB 309801 Grunberg, S. M. , Weeks, J. , Magnan, W. F. , Herndon, J. 2nd ... - - J Support Oncol - 2009 Manuscript - Primary - Primary - Disparities - CALGB-309801
A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603) O'Reilly, Eileen M. , Niedzwiecki, Donna , Hall, Margaret ... - - Oncologist - 2010 Manuscript - Primary - Primary - GI - CALGB-80603
